Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients

Medicine

Volumn 78, Issue 4, 1999, Pages 209-219

  Francès, Camille ^a   Papo, Thomas ^a   Wechsler, Bertrand ^a   Laporte, Jean Luc ^a   Biousse, Valérie ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; LIVEDO RETICULARIS; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SNEDDON SYNDROME;

ADOLESCENT; ADULT; AGE OF ONSET; ANTIBODIES, ANTIPHOSPHOLIPID; CHILD; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; SNEDDON SYNDROME; TREATMENT OUTCOME;

EID: 0032870650     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199907000-00001     Document Type: Article

References (53)

1. Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid/cofactor syndromes. 2. A variant in patients with systemic lupus erythematosus with antibodies to beta(2)-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 24: 1545-51, 1997.
2. Alegre VA, Winkelman RK. Histopathologic and immunofluorescence study of skin lesions associated with circulating anticoagulant. J Am Acad Dermatol 19: 117-24, 1988.
3. Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus. Lancet 342: 988-89, 1993.
4. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Outt HJ, Harris EN, Vilardell-Torres M, Hughes GRV. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68: 366-74, 1989.
5. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein-1 than with antiphospholipid antibodies. J Rheumatol 22: 1899-1906, 1995.
6. Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: A primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 101: 472-81, 1996.
7. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, Ingelmo M. Chorea in the antiphospholipid syndrome: Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 76: 203-12, 1997.
8. Champion RH, Rook A. Livedo reticularis. Proc R Soc Med 53: 961-62, 1960.
9. Ehrmann S. Ein neues Gefaβsymptom bei Lues. Wien Med Wochenschr 57: 777-82, 1907.
10. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: A review of neuropathological findings in 57 cases, 1955-1977. Semin Arthritis Rheum 8: 212-21, 1979.
11. Englert HJ, Loizou S, Derue GGM, Walport MJ, Hughes GRV. Clinical and immunologic features of livedo reticularis in lupus: A case-control study. Am J Med 87: 408-10, 1989.
12. Font J, Lopez-Soto A, Cervera R, Balasch J, Pallares L, Navarro M, Bosch X, Ingelmo M. The "primary" antiphospholipid syndrome: Antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 9: 69-75, 1991.
13. Frances C, Piette JC. La definition du syndrome de Sneddon: Contorsions entre mailles et circonvolutions. Ann Dermatol Venereol 121: 293-96, 1994.
14. Frances C, Piette JC, Viard JP, Tourbah A. Anti-β2-glycoprotein-1 antibodies in Sneddon's syndrome [letter]. Dermatology 186: 273, 1993.
15. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 37: 568-71, 1994.
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40: 1725, 1997.
17. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93: 1579-87, 1996.
18. Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures. Acta Neurol Scand 79: 114-18, 1989.
19. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 47: 337-69, 1968.
20. Kalashnikova LA, Nasonov EL, Borisenko VV, Usman VB, Prudnikova LZ, Kovaljov VU, Kushekbaeva AF. Sneddon's syndrome: Cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol 9: 357-61, 1991.
21. Kalashnikova LA, Nasonov EL, Stoyanovich LZ, Kovaljov VU, Kosheleva NM, Reshetnyak TM. Sneddon's syndrome and the primary antiphospholipid syndrome. Cerebrovasc Dis 4: 76-82, 1994.
22. Kent M, Alvarez F, Vogt E, Fyffe R, Ah-Kau NG, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol 24: 1725-33, 1997.
23. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vazquez JJ, Pare C, Ingelmo M, Oliver J. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335: 1541-44, 1990.
24. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 332: 993-97, 1995.
25. Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 68: 795-815, 1988.
26. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 157: 2101-8, 1997.
27. Levine SR, Brey RL. Neurological aspects of antiphospholipid antibody syndrome. Lupus 5: 347-53, 1996.
28. Levine SR, Langer SL, Albers JW, Welch KMA. Sneddon's syndrome: An antiphospholipid antibody syndrome? Neurology 38: 798-800, 1988.
29. Levine SR, Welch KMA. The spectrum of neurologic disease associated with antiphospholipid antibodies: Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 44: 876-83, 1987.
30. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, Chuang CY, Chen CY, Tsai MC. Anticardiolipin antisera from lupus patients with seizures reduce a gaba receptor-medicated chloride current in snail neurons. Life Sci 54: 1119-25, 1994.
31. Lipsker D, Piette JC, Laporte JL, Maunoury L, Frances C. Annular atrophic lichen planus and Sneddon's syndrome. Dermatology 195: 402-3, 1997.
32. Piette JC. 1996 Diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: A "mission impossible"? Lupus 5: 354-63, 1996.
33. Piette JC. Updating the American College of Rheumatology criteria for systemic lupus erythematosus: Comment on the letter by Hochberg. Arthritis Rheum 41: 751, 1998.
34. Piette JC, Wechsler B, Frances C, Godeau P. Systemic lupus erythematosus and the antiphospholipid syndrome: Reflections about the relevance of ARA criteria. J Rheumatol 19: 1835-37, 1992.
35. Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for the primary antiphospholipid syndrome. J Rheumatol 20: 1802-4, 1993.
36. Pinol Aguade J, Ferrandiz C, Ferrer Roca O, Ingelmo M. Livedo reticularis y accidentes cerebro-vasculares. Med Cutan Ibero Lat Am 3: 257-65, 1975.
37. Rautenberg G, Hennerici M, Aulich A, Holzke E, Lakomel HG. Immunosuppressive therapy and Sneddon's syndrome. Lancet 2: 629-30, 1988.
38. Roubey RAS. Immunology of the antiphospholipid syndrome. Arthritis Rheum 39: 1444-54, 1996.
39. Sepp N, Zelger B, Schuler G, Romani N, Fritsch P. Sneddon's syndrome. An inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence. Am J Surg Pathol 19: 448-53, 1995.
40. Sitzer M, Songher D, Siebler M, Specker C, Rademacher J, Janda I, Aulich A, Steinmetz H. Cerebral microembolism in patients with Sneddon's syndrome. Arch Neurol 52: 271-75, 1995.
41. Sneddon IB. Cerebrovascular lesions and livedo reticularis. Br J Dermatol 77: 180-85, 1965.
42. Special report from the world health organization. Stroke - 1989. Recommendations on stroke prevention, diagnosis and therapy. Stroke 20: 1407-31, 1989.
43. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-77, 1982.
44. Tourbah A, Piette JC, Iba-Zizen MT, Lyon-Caen O, Godeau P, Frances C. The natural course of cerebral lesions in Sneddon's syndrome. Arch Neurol 54: 53-60, 1997.
45. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, Harle JR, Reynaud L, Weiller PJ. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 103: 33-37, 1997.
46. Vianna JL, Khamasta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M. Vilardell M, Hughes GRV. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med 96: 3-9, 1994.
47. Viard JP, Amoura Z, Bach JF. Association of anti-β2-glycoprotein I with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 93: 181-86, 1992.
48. Weinstein C, Miller MH, Axtens R, Buchanan R, Littlejohn GO. Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 123: 596-600, 1987.
49. Westerman EM, Miles JM, Backonja M, Sundstrom WR. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum 35: 1038-41, 1992.
50. Zelger B, Herold M. The mystery of antiphospholipid antibodies in Sneddon's syndrome. [Reply to letter.] Arch Dermatol 130: 520, 1994.
51. Zelger B, Sepp N, Schmid KW, Hintner HH, Klein GG, Fritsch PO. Life history of cutaneous vascular lesions in Sneddon's syndrome. Hum Pathol 23: 668-75, 1992.
52. Zelger B, Sepp N, Stockhammer G, Dosch E, Hilty E, Ofner D, Aichner F, Fritsch O. Sneddon's syndrome. A long term follow up of 25 patients. Arch Dermatol 129: 437-47, 1993.
53. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 100: 613-19, 1997.